GOA Therapeutics Corporation is a biotechnology company developing potential first-in-class drug candidates to address significant unmet medical needs. The company is advancing a multidisciplinary program spanning drug discovery, enzyme engineering, preclinical development, regulatory strategy, and commercialization. Its lead program, GOA26, is the first drug candidate designed to rapidly lower blood alcohol concentration and is advancing toward IND filing and clinical studies, backed by successful IND-enabling testing and a growing global IP portfolio of more than 30 patent filings. Alcohol contributes to an estimated 178,000 U.S. deaths and $249 billion in economic costs annually — underscoring the scale of the problem GOA26 aims to address.